Avoro Capital Slams Merck's $11.5B Acceleron Deal
Avoro Capital Advisors protested against an $11.5 billion offer by Merck & Co. to buy Acceleron Pharma Inc., a rare disease drug company it partly owns, in an open letter Thursday...To view the full article, register now.
Already a subscriber? Click here to view full article